Please assess the completion status of the following clinical trial:

Trial Title: A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients (40 years of age or older) with an established diagnosis of COPD based upon medical history who are being admitted to the hospital to treat an exacerbation of COPD;~2. Normal prothrombin time and activated partial thromboplastin time; Platelet count; hemoglobin and hematocrit~Exclusion Criteria:~1. Certain diseases such as:~   * asthma;~  * left heart failure or pulmonary embolism;~  * lung cancer;~  * pneumonia~  * liver or kidney disease~  * blood clotting disorder~  * Positive HIV or hepatitis tests~  * GI bleeding, physical trauma with bleeding, any disease with bleeding within 60 days of study entry~2. Certain medications such as:~   * Plavix®~  * Warfarin~  * Heparin therapy~  * Certain antibiotics~3. Exacerbations that are too severe (requiring intubation and mechanical ventilation)~4. Women of child-bearing potential, pregnancy or breast-feeding~5. Unable or unwilling to provide informed consent and follow study procedures.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
- 0.9% Sodium Chloride (Type: PLACEBO_COMPARATOR): Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
- Randomized, Blinded, ODSH Arm (Type: ACTIVE_COMPARATOR): Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).